Onizawa S, Watanabe S, Yagura T, Yasutomi M, Yamamura Y
Gan. 1976 Jun;67(3):371-8.
The level of carcinoembryonic antigen (CEA) in the plasma was measured in 258 patients, consisting of 198 patients with various cancers and 60 with various non-malignant diseases. As the normal control, the plasma CEA level was examined in 330 apparently healthy individuals and the value was 3.1 +/- 1.1 ng/ml on the average. If the level higher than 4.2 ng/ml could be assumed to be above the normal, 109 out of 198 (55%) patients with malignant diseases were considered to show abnormally elevated CEA values. Based on the above criterion, the CEA titer was abnormally elevated only in 11 out of 60 cases (18%) without cancers. Among cancerous patients, the ones with carcinomas of the digestive tract and the lung exhibited a positive titer of CEA higher than 10.1 ng/ml. When the relationship between the plasma CEA level and histological findings in patients with lung cancer was examined, cases with the adenocarcinoma had more elevated titers than those with any other types of lung cancer. It was also found, by the serial estimation of plasma CEA, that the titer dropped after a successful therapy but elevated again with the recurrence of cancer. Repeated estimation of Cea is thought to be valuable as an indicator for clinical phases of cancer patients.
对258例患者的血浆癌胚抗原（CEA）水平进行了检测，其中包括198例患有各种癌症的患者和60例患有各种非恶性疾病的患者。作为正常对照，对330名明显健康的个体检测了血浆CEA水平，其平均值为3.1±1.1 ng/ml。如果将高于4.2 ng/ml的水平视为高于正常水平，则198例（55%）恶性疾病患者中有109例被认为CEA值异常升高。根据上述标准，60例无癌症患者中只有11例（18%）的CEA滴度异常升高。在癌症患者中，消化道癌和肺癌患者的CEA阳性滴度高于10.1 ng/ml。当研究肺癌患者血浆CEA水平与组织学结果之间的关系时，腺癌患者的滴度高于其他类型肺癌患者。通过对血浆CEA的连续检测还发现，成功治疗后滴度下降，但癌症复发时又会再次升高。反复检测CEA被认为作为癌症患者临床分期的指标具有重要价值。
